Evidence map›Paper›PMID 35047717›Full record

ArticleJournal of the Endocrine Society2022

Bone Age Maturation and Growth Outcomes in Young Children with CAH Treated with Hydrocortisone Suspension.

Heba Al-Rayess, O Yaw Addo, Elise Palzer, Mu'taz Jaber, Kristin Fleissner, James Hodges, Richard Brundage, Bradley S Miller, Kyriakie Sarafoglou

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the Endocrine Society, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.1field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Heba Al-RayessDivision of Endocrinology, Department of Pediatrics, University of Minnesota Medical School, Minneapolis, MN 55454, USA.
O Yaw AddoDepartment of Global Health, Rollins School of Emory University, Atlanta, GA 30322, USA.
Elise PalzerDivision of Biostatistics, University of Minnesota School of Public Health, Minneapolis, MN 55455, USA.
Mu'taz JaberDepartment of Experimental and Clinical Pharmacology, University of Minnesota College of Pharmacy, Minneapolis, MN 55455, USA.
Kristin FleissnerDivision of Endocrinology, Department of Pediatrics, University of Minnesota Medical School, Minneapolis, MN 55454, USA.
James HodgesDivision of Biostatistics, University of Minnesota School of Public Health, Minneapolis, MN 55455, USA.
Richard BrundageDepartment of Experimental and Clinical Pharmacology, University of Minnesota College of Pharmacy, Minneapolis, MN 55455, USA.
Bradley S MillerDivision of Endocrinology, Department of Pediatrics, University of Minnesota Medical School, Minneapolis, MN 55454, USA.
Kyriakie SarafoglouDivision of Endocrinology, Department of Pediatrics, University of Minnesota Medical School, Minneapolis, MN 55454, USA.ORCID https://orcid.org/0000-0002-5741-3629
University of Minnesota · USUniversity of Minnesota Medical Center · USEmory University · US

Funding

Pre-Faculty Research Training in Pediatric EndocrinologyT32DK065519 · NIDDK · UNIVERSITY OF MINNESOTA TWIN CITIES · PI BELLIN, MELENA D. · 2004 to 2024
$3.6M
NIDDK NIH HHS T32 DK065519
6 · The paper itself

Abstract

backgroundYoung children with congenital adrenal hyperplasia (CAH) require small doses (0.1-1.25 mg) of hydrocortisone (HC) to control excess androgen production and avoid the negative effects of overtreatment. The smallest commercially available HC formulation, before the recent US Food and Drug Administration approval of HC granules, was a scored 5-mg tablet. The options to achieve small doses were limited to using a pharmacy-compounded suspension, which the CAH Clinical Practice Guidelines recommended against, or splitting tablets into quarters or eighths, or dissolving tablets into water.

methodsCross-sectional chart review of 130 children with classic CAH treated with tablets vs a pharmacy-compounded alcohol-free hydrocortisone suspension to compare growth, weight, skeletal maturation, total daily HC dose, and exposure over the first 4 years of life.

resultsNo significant differences were found in height, weight, or body mass index

conclusionsOur data indicate that treatment with alcohol-free HC suspension decreased androgen exposure as shown by lower bone age

Indexed as

adrenal insufficiencybone agecongenital adrenal hyperplasiagrowthhydrocortisonesuspension

Identifiers

PMID35047717
PMCPMC8758402
OpenAlexW4200207115

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.